Suggested:
The pharmaceutical company Moderna aims to develop a vaccine for bird flu in humans.
The US Department of Health has terminated funding for Moderna's mRNA vaccine project against avian flu (H5N1) amounting to $776 million. The decision was made due to safety concerns and inadequate testing of the mRNA technology. Further support was deemed scientifically and ethically unjustifiable.
The mRNA technology remains a focal point of criticism according to the US Department of Health. It also criticized the previous government for allegedly concealing legitimate safety concerns from the public.
Despite the setback from the Department of Health, Moderna released interim results from a Phase 1/2 study where the vaccine was tested on 300 healthy adults aged 18 and above. The company reported a strong immune response and a good safety profile. Moderna emphasized that despite the funding gap, they will explore alternative ways to continue developing the vaccine.
